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DAVID A. HOLLANDER, MD, MBA, 6 AND MICHAEL E. STERN, PHD6ABSTRACT Purpose: To investigate changes in signs,
symptoms, and tear cytokines following punctal plug
occlusion in patients with dry eye. Methods: A single-center
study was conducted at Singapore Eye Research Institute.
Nonabsorbable punctal plugs were inserted in the lower
punctum of both eyes in patients with moderate dry eye.
Over 3 weeks, in the more severe eye, dry eye symptoms,
ﬂuorescein corneal staining, Schirmer I (without topical
anesthesia) test, tear ﬁlm breakup time (TFBUT), and safety
were assessed. Cytokine and matrix metalloproteinase-9
(MMP-9) levels in tear samples were measured. Results:
Twenty-nine patients (mean age 49.8 years) with moderate
dry eye were evaluated. At baseline, mean (standardAccepted for publication December 2015.
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THE OCULAR SURFACE / APRIL 2016, VOLdeviation) global symptoms score was 53.8 (26.5), Schirmer I
test score was 5.1 (2.8) mm, and TFBUT was 2.2 (0.6) seconds.
After 3 weeks, punctal occlusion signiﬁcantly reduced global
irritation symptoms score (P<.001) and decreased ﬂuores-
cein staining in all zones (P<.01) except the inferior zone
(P¼.42). No signiﬁcant association between levels of cyto-
kines or MMP-9 and either TFBUT or global irritation symp-
toms were observed at baseline. Levels of several cytokines
andMMP-9 were higher in patients with Schirmer I test scores
8 mm at baseline. After 3 weeks of punctal occlusion, no
signiﬁcant changes in overall cytokine or MMP-9 levels were
observed. Conclusions: Punctal plug occlusion provided
symptomatic relief and reduced ﬂuorescein staining in all
except the inferior zone. However, insertion of punctal plugs
had minimal effect on tear cytokines and MMP-9 levels,
suggesting a need for earlier treatment with anti-
inﬂammatory agents for management of dry eye disease.
KEY WORDS cytokine, dry eye, matrix metalloproteinase,
punctal plug, tear
I. INTRODUCTIONT he International Dry Eye WorkShop (DEWS; 2007)deﬁned dry eye as a multifactorial disease of thetears and ocular surface system producing discom-
fort, visual disturbance, and tear ﬁlm instability potentially
leading to ocular surface system damage. In addition, dry
eye disease is further characterized by increased osmolarity
of the tear ﬁlm and inﬂammation of the ocular surface.1
Dry eye also impacts daily activities such as reading, driving,
work especially involving computer use, and social activities
with signiﬁcant effects on patient quality of life.2,3
Dry eye disease is a burden worldwide. Estimates of the
global prevalence in individuals aged 50 years or older range
from 5% to 30%.4 In Japan and China, dry eye has been re-
ported to affect up to 22% of adults ages 40 years and
older,5,6 and as many as 60% to 70% of young to middle-
aged Japanese video terminal users.7 Among Asian patients
older than 65 years, prevalence may be as high as 60% or
80%, depending on whether diagnosis is based on. 14 NO. 2 / www.theocularsurface.com 233
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respectively.8 Age, contact lens wear, ocular surgery, diet,
smoking, history of allergy or diabetes, as well as environ-
mental stimuli have been reported as risk factors leading
to tear ﬁlm instability and development of dry eye.4,9
Chronic, T-cellemediated inﬂammation involving the
ocular surface and lacrimal glands has been demonstrated
to have a prominent role in the development and progres-
sion of dry eye disease. Stress to the ocular surface activates
signaling pathways in a variety of cell types, leading to
expression of proinﬂammatory proteins (including cyto-
kines/chemokines, proteinases, growth factors, and other
mediators), further damage, and the development of a
self-perpetuating inﬂammatory cycle.10-12 Punctal occlusion
is a common treatment option for patients with dry eye, and
improvements in clinical signs and symptoms have been re-
ported after insertion of punctal plugs.13-15 However, there
is limited evidence that punctal occlusion alters the underly-
ing pathologic inﬂammation affecting tear ﬁlm stability and
cytokine composition in dry eye disease. Insertion of punctal
plugs has been shown to temporarily reduce tear clearance,16
which may affect cytokine levels and inﬂammation. In pa-
tients with conjunctival chalasis or nasal conjunctivochala-
sis, a common ocular surface condition with delayed tear
clearance, higher levels of interleukin (IL)-6, IL-8, IL-1b,
and tumor necrosis factor (TNF)-a have been reported.17,18
The present longitudinal study evaluated the effects of
punctal occlusion in patients with dry eye disease. Changes
in the severity and frequency of symptoms and clinical signs
of dry eye after bilateral insertion of punctal plugs were
assessed with a focus on effects of occlusion on tear cytokine
and matrix metalloproteinase (MMP) levels.II. MATERIALS AND METHODS
This prospective, interventional study was conducted be-
tween October 2012 and January 2013 at the Singapore Eye
Research Institute (ClinicalTrials.gov identiﬁer:
NCT01684436). The study was performed in accordance234 THE OCULAR SURFACE / APRIL 2016, Vto principles of the Declaration of Helsinki, the Interna-
tional Conference on Harmonisation, Good Clinical Practice
guidelines, and all applicable laws and regulations. The
study protocol and one amendment to the protocol were
reviewed and approved by the SingHealth Centralised Insti-
tutional Review Board, and all patients provided written
informed consent prior to starting study treatment.
A. Patients
Study eligibility was determined at the screening visit.
Patients (21 years of age or older) were enrolled if they
had moderate dry eye disease with persistent symptoms
(light sensitivity, gritty or scratchy sensation, burning or
stinging, blurred vision, vision that ﬂuctuates with blinking,
and vision that improves with artiﬁcial tears) and two or
more symptoms that were grade 3 or greater (i.e., occurring
often or all the time), corneal ﬂuorescein staining greater
than mild in severity (i.e., any staining beyond a periphery
of 1 mm from the limbus), tear ﬁlm breakup time (TFBUT)
10 seconds, and Schirmer I (without topical anesthetic)
test score 10 mm.
Exclusion criteria included severe meibomian gland
dysfunction (i.e., no more than two meibomian plugs per
eyelid and no signiﬁcant meibomian oriﬁce irregularity), ste-
roids or cyclosporine use within the last 3 months, insertion
of punctal plugs within the last 3 months or presence of
punctal plugs at the start of the study, and contact lens
use within the last 7 days prior to start of study or during
the course of the study, ocular conditions (other than dry
eye) requiring the use of eye drops, and pterygium or other
small corneal/conjunctival lesions or degeneration (e.g., Sal-
zmann nodular degeneration). Also excluded were patients
who had undergone laser in situ keratomileusis within the
prior year; cataract or other ocular surgery within the last
3 months; corneal grafts; systemic disease such as diabetes,
Sjögren syndrome, rheumatoid arthritis, or thyroid disease;
and women of childbearing age who were nursing, pregnant,
or considering becoming pregnant.
B. Punctal Plug Insertion and Clinical Assessments
Punctal plugs (Parasol Punctal Occluder; Odyssey
Medical, Beaver-Visitec International, Inc., Waltham, MA,
USA) were inserted into the lower punctum of both eyes af-
ter baseline assessments. In the event that punctal plugs
were lost during the course of the study, patients returned
within 2 days for reinsertion of new plugs. In cases in which
the loss of punctal plugs was not noticed, only data collected
up to the last known presence of the plug was recorded and
used for analysis. Patients were allowed to continue the use
of lubricating tear drops, but cyclosporine, steroids, and/or
doxycycline were not permitted during the course of the
study.
At baseline prior to insertion of punctal plugs, and at
week 1 and week 3 visits, patients had dry eye symptoms,
Schirmer I test, TFBUT, and corneal ﬂuorescein staining as-
sessments, and underwent routine anterior segment slit-
lamp microscope evaluation performed in the speciﬁcOL. 14 NO. 2 / www.theocularsurface.com
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cating tear drops within 30 minutes of the study visit. Dry
eye symptoms were evaluated using a visual analog scale.
Scores for frequency and severity of symptoms were
collected via a patient questionnaire and recorded separately
on a 100-mm line corresponding to the degree of the symp-
tom, and global scores for irritation, blurred vision, and light
sensitivity were calculated with higher scores indicating
greater severity of disease.19
Prior to any anterior segment assessments, Schirmer I
test was performed and the extent of wetting of each strip
placed over the inferior temporal half of the lower lid
margin in each eye was measured and recorded over 5 mi-
nutes. The Schirmer test strips were also used to collect
tear protein samples (see Section II.C). TFBUT was
measured after instillation of the ﬂuorescein dye prior to
assessing corneal staining. Fluorescein dye was instilled us-
ing ﬂoret strips (Laboratories Chauvin S.A., Aubenas,
France) after wetting with a drop of normal saline and
shaking off excess ﬂuid. Corneal staining was then assessed
in ﬁve corneal zones (central, superior, inferior, nasal, and
temporal) following instillation of ﬂuorescein dye, and
graded on a scale of 0e4 (half-unit increments were
allowed).20 The eye with the more severe disease was deter-
mined based on Schirmer test, TFBUT, or corneal ﬂuores-
cein staining, and was designated the study eye.
Safety was assessed by monitoring adverse events, intra-
ocular pressure, and visual acuity measurements, as well as
questions on pain and slit-lamp examination of swelling
around the punctal area.Table 1. Patient baseline characteristics
Baseline character-
istic, mean (SD) Total (n [ 29) Female (n
Age, years 49.8 (14.1) 51.5 (1
Global symptoms score
Irritation 53.8 (26.5) 59.1 (2
Blurred vision 27.1 (33.8) 24.0 (3
Light sensitivity 31.1 (37.1) 31.8 (3
Corneal staining grade
Central 1.0 (1.0) 1.0 (1
Nasal 0.7 (0.9) 0.7 (1
Temporal 0.7 (1.0) 0.7 (1
Superior 0.6 (0.9) 0.7 (1
Inferior 1.3 (1.0) 1.2 (1
Schirmer I test score,
mm
5.1 (2.8) 5.0 (2
TFBUT, sec 2.2 (0.6) 2.3 (0
* P value for the difference between male and female patients.
NA ¼ not applicable; SD ¼ standard deviation; TFBUT ¼ tear ﬁlm breaku
THE OCULAR SURFACE / APRIL 2016, VOLC. Tear Inﬂammatory Protein Assessments
Levels of 15 cytokines and MMP-9 were analyzed in tear
samples using a bead-based indirect immunoﬂuorescent
assay (Beadlyte; EMD Millipore, Billerica, MA, USA) as
described previously.21,22 Tear protein samples were
collected at the same time and using the same test strips
as the Schirmer test. At baseline and the week 1 and 3 study
visits, tear proteins were collected prior to TFBUT and
corneal staining to ensure that proteins were not washed
out by reﬂex tearing. Schirmer test strips with tear protein
samples from both eyes were cut in half (one half to be
used for tear cytokine level analysis and one half for prote-
omics analysis) and stored in 1.5-mL Eppendorf tubes
at 80C until the time of analysis. Tear samples were
diluted in 50-mL assay buffer and agitated for 20 minutes
at 4C, then 10-mL aliquots of the diluted samples were
assayed. The multiplex bead-based assay detects free, total,
and non-degraded forms of the cytokines and MMP-9.
D. Data Analysis and Statistical Methods
Study data were collected and managed by the Singapore
Eye Research Institute trial management team. Changes in
global symptom scores, corneal ﬂuorescein staining, TFBUT,
Schirmer test, and tear cytokines andMMP-9 levels were eval-
uated from baseline up to 3weeks following insertion of punc-
tal plugs. For cytokine and MMP-9 analyses, concentrations
were normalized to the amount of wetting (plus 3 mm) of
Schirmer test strips used to collect tears for the multiplex
bead-based assays. Univariate analyses of individual parame-
ters, as well as multivariate analyses adjusting for covariates,[ 23) Male (n [ 6) P value*
4.5) 44.7 (10.9) NA
3.5) 33.6 (30.0) .03
1.6) 38.7 (42.6) .35
7.9) 28.0 (37.1) .83
.0) 0.8 (1.0) .65
.0) 0.7 (0.8) .99
.0) 1.0 (1.0) .59
.0) 0.2 (0.4) .20
.0) 1.8 (0.6) .22
.7) 5.2 (3.4) .93
.6) 1.8 (0.3) .04
p time.
. 14 NO. 2 / www.theocularsurface.com 235
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Changes in cytokine levels were also assessed in subgroups
of patients demonstrating improvement in global irritation
symptoms score versus those showing no improvements in
global irritation symptoms score following punctal occlusion.
Responders were deﬁned as patients with improvement in
symptoms after occlusion, where global symptom scores at
week 3 minus week 0 were <0.
All statistical analyses were performed using SPSS for
Windows, Version 12.0 (IBM Corporation, Armonk, NY,
USA) and P<.05 was used to determine differences that
were statistically signiﬁcant. As this was a pilot study, no po-
wer analysis and sample-size calculations were performed.40
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*III. RESULTS
A. Patients and Baseline Characteristics
A total of 30 patients were enrolled and had punctal
plugs inserted bilaterally in the lower puncta. This report
is based on 29 patients who completed the study; 1 patient
withdrew consent following the baseline visit. The mean
(standard deviation [SD]) age was 49.8 (14.1) years and
the majority of patients were female (n¼23). Female pa-
tients had a worse global symptoms irritation scoreTable 2. Patients’ use of lubricating eye drops prior to
enrollment
Previous
treatments
Number of
patients*
Daily use
(range)y
Artiﬁcial tears (without preservatives)
Tear Naturale
Free
10 <1e5
Refresh Endura 3 1e12
Refresh Plus 3 1e4
Refresh Classic 2 <1
Artiﬁcial tears (with preservatives)
Systane Ultra 4 1e20
Hialid 1 4
Eyemo 1 3
Hypomellose 1 <1
Eye ointment/gel
Duratears
ointment
7 <1e2
Vidisic gel 2 1
Blephagel 1 <1
No prior
treatment
5 e
* Patients may have used more than one lubricating eye drop
prior to baseline.
y <1 indicates occasional non-daily use of lubricating eye drops.
236 THE OCULAR SURFACE / APRIL 2016, V(P¼.03) than male patients at baseline. Corneal ﬂuorescein
staining assessed in all zones at baseline was not signiﬁcantly
different in female and male patients. In contrast, at base-
line, males had worse TFBUT than females (P¼.04). No
other signiﬁcant differences were observed in dry eye signs
or symptoms between the groups at baseline (Table 1).
Lubricating eye drop use prior to study enrollment is sum-
marized in Table 2.B. Effects of Punctal Occlusion on Clinical Symptoms
and Signs of Dry Eye
At baseline, global irritation symptoms score (mean
[SD]) was 53.8 (26.5) and decreased to 36.2 (24.9) after
3 weeks of punctal occlusion (Figure 1, top). The change
in irritative symptoms from baseline was statistically0
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Figure 1. Mean global symptom scores for irritation, blurred vision,
and light sensitivity following punctal occlusion. Global irritation symp-
toms scores (top) decreased from baseline up to 3 weeks after insertion
of punctal plugs. Blurred vision scores (middle) and light sensitivity
scores (bottom) did not change signiﬁcantly after punctal occlusion.
Data points represent mean  standard error. *P<.001 compared with
baseline by general linear model (repeat measures) analysis.
OL. 14 NO. 2 / www.theocularsurface.com
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Figure 2. General linear
model (repeat measure) anal-
ysis of corneal staining.
Corneal ﬂuorescein staining
signiﬁcantly decreased after
punctal occlusion in central,
nasal, superior, and temporal
zones (P<.01), but not in the
inferior zone (P¼.42), after
3 weeks of punctal occlusion.
Data points represent
mean  standard error.
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Figure 3. General linear model (repeat measures) analysis of Schirmer I
test scores and tear ﬁlm breakup time (TFBUT) changes following
punctal occlusion. No statistically signiﬁcant improvement in Schirmer I
test scores (top) and TFBUT (bottom) were observed up to 3 weeks after
punctal occlusion. Data points represent mean  standard error.
DRY EYE SIGNS, SYMPTOMS, AND TEAR CYTOKINES AFTER PUNCTAL OCCLUSION / Tong, et alsigniﬁcant at the week 3 visit (P<.001) based on general
linear model (repeat measure) analysis. Both males and fe-
males demonstrated improvements in global irritative symp-
toms over time, with the change in irritative symptoms
remaining signiﬁcant after adjusting for age and gender
(P¼.02). Compared with baseline, global blurred vision
and light sensitivity symptom scores remained relatively
the same after punctal occlusion (Figure 1, middle and
bottom).
At 3 weeks, corneal staining was signiﬁcantly decreased
from baseline in the central, nasal, superior, and temporal
corneal zones (P<.01), but not in the inferior zone
(P¼.42) (Figure 2). In addition, no statistically signiﬁcant
improvements were observed at week 1 or week 3 compared
with baseline in either Schirmer I test scores or TFBUT
(Figure 3, top and bottom).
C. Effects of Punctal Occlusion on Tear Cytokine and
MMP-9 Levels
Cytokine and MMP-9 levels at baseline and after 1 week
and 3 weeks of punctal occlusion are presented in Table 3.
At week 3, cytokines and MMP-9 levels were similar to
levels at baseline. Analysis of the relationship between base-
line cytokine and MMP-9 levels and clinical signs and
symptoms revealed that patients with low baseline Schirmer
I test scores (8 mm) had elevated levels of tear cytokines
and MMP-9 compared with patients with higher baseline
Schirmer I test scores (>8 mm) (Table 4). Similarly, patients
with baseline Schirmer I test scores 5 mm had higher cyto-
kine and MMP-9 levels compared with patients with base-
line Schirmer I test scores >5 mm (data not shown).
Cytokine levels that were higher in patients with low
Schirmer I test scores at baseline remained elevated up to
3 weeks after punctal occlusion. No associations were found
between cytokine or MMP-9 levels and global irritation
symptoms scores or TFBUT at baseline.THE OCULAR SURFACE / APRIL 2016, VOLThe following associations were observed between base-
line cytokine levels and corneal staining at baseline, but
there were no consistent patterns in cytokine levels across
the ﬁve corneal zones assessed: superior corneal staining
was associated with IL-6 (P¼.026) and TNF-a (P¼.001)
levels; inferior corneal staining was associated with IL-1b
(P¼.005) and IL-2 (P¼.033) levels; and temporal corneal. 14 NO. 2 / www.theocularsurface.com 237
Table 3. Tear cytokine and MMP-9 levels at baseline, week 1, and week 3 after punctal occlusion
Concentration pg/mL/mm,
mean (SD)
Assessment time point
Baseline Week 1 Week 3
TNF-a 1.5 (1.5) 1.9 (1.9) 1.4 (1.2)
IL-2 0.9 (0.6) 1.4 (1.4) 1.1 (1.1)
IL-12 9.1 (10.0) 9.8 (9.3) 7.3 (6.1)
IL-1b 0.6 (0.4) 0.9 (0.7) 1.1 (1.0)
IFN-g 2.2 (2.0) 3.2 (3.2) 3.1 (2.7)
IL-13 29.8 (26.5) 32.4 (28.5) 29.1 (23.4)
RANTES 21.2 (15.6) 21.4 (18.4) 29.6 (27.0)
IP-10 2384.9 (1198.1) 2873.1 (1631.4) 2769.2 (1479.5)
MCP-1 49.1 (46.9) 81.3 (82.4) 68.1 (62.1)
IL-4 17.7 (21.6) 15.0 (15.4) 9.8 (8.3)
MIP-1a 0.6 (0.6) 0.6 (0.5) 0.6 (0.7)
IL-6 6.1 (6.7) 5.8 (5.7) 4.3 (3.7)
IL-10 4.7 (3.5) 5.3 (4.3) 4.0 (3.4)
IL-17a 0.6 (0.5) 1.0 (1.8) 0.6 (0.4)
MMP-9 1519.8 (1516.9) 2166.9 (2712.0) 1445.5 (1415.1)
IL-8 74.0 (55.0) 78.6 (67.2) 61.1 (57.2)
IL ¼ interleukin; IFN ¼ interferon; IP ¼ interferon-gammaeinduced protein; MCP ¼ monocyte chemotactic protein; MIP ¼ macrophage in-
ﬂammatory protein; MMP ¼ matrix metalloproteinase; RANTES ¼ regulated on activation, normal T-cell expressed and secreted; SD ¼ standard
deviation; TNF ¼ tumor necrosis factor.
DRY EYE SIGNS, SYMPTOMS, AND TEAR CYTOKINES AFTER PUNCTAL OCCLUSION / Tong, et alstaining was associated with IL-12 (P¼.018) and IL-13
(P¼.021) levels. These associations were not signiﬁcant
when adjusted for age.
Linear mixed-model analyses revealed that changes in
interferon-gammaeinducible protein (IP)-10 (P<.001)
and macrophage inﬂammatory protein (MIP)-1a (P¼.032)
levels after insertion of punctal plugs were associated with
global irritation symptoms score. Higher levels of MIP-1a
(but not IP-10) at baseline were observed among patients
who demonstrated improvement in global irritation symp-
toms score following punctal occlusion compared with those
patients without improvements in their global irritation
symptoms score (Figure 4, top and bottom).
D. Safety
No adverse events were reported following bilateral
insertion of punctal plugs during the course of the 3-week
study.
IV. DISCUSSION
Inﬂammation of the ocular surface has been shown to
play a critical role in the pathogenesis of dry eye.1,10-12
Changes in tear cytokine and MMP-9 levels have been re-
ported in patients with dry eye disease or dysfunctional238 THE OCULAR SURFACE / APRIL 2016, Vtear syndrome compared with asymptomatic healthy con-
trols, including increased levels of IL-1b, TNF-a, interferon
(IFN)-g, IL-6, IL-8, IL-16, and MMP-9.23-26 In the earlier
study by Lam et al, signiﬁcant correlations were observed
between IL-6 levels and ocular irritation symptoms, and be-
tween a number of cytokines and chemokines and clinical
parameters including Schirmer I test scores, corneal ﬂuores-
cein staining, and conjunctival lissamine green staining in
patients with dysfunctional tear syndrome with or without
meibomian gland disease.25 Treatment recommendations
for dry eye disease developed by the International Task
Force Delphi Panel emphasize that inﬂammation either trig-
gers or maintains dry eye in most cases, even in the absence
of clinically evident inﬂammation.27 A major focus of this
study was the impact of punctal occlusion on ocular inﬂam-
mation as reﬂected in tear cytokine levels.
Longitudinal changes in tear cytokine levels have been
evaluated in daily contact lens wearers28 and in individuals
using contact lens solutions,29 in patients administered
preservative-free or preserved timolol 0.5% eye drops30
and subconjunctival anti-vascular endothelial cell growth
factor injections,31 in patients with allergic keratoconjuncti-
vitis secondary to nasal allergy,32 and following femtosecond
laser-assisted laser in situ keratomileusis or small-incisionOL. 14 NO. 2 / www.theocularsurface.com
Table 4. Baseline cytokine and MMP-9 levels prior to punctal occlusion in patients with Schirmer I test scores 8 mm or
>8 mm at baseline
Concentration pg/mL/mm,
mean (SD)
Baseline Schirmer I test score
£8 mm (n[23) >8 mm (n[6) P value*
TNF-a 1.0 (0.7) 0.4 (0.3) <.001
IL-2 0.9 (0.5) 0.3 (0.2) .003
IL-12 7.5 (6.4) 4.1 (2.6) .011
IL-1b 0.7 (0.4) 0.4 (0.2) .058
IFN-g 2.1 (1.5) 1.0 (0.8) .073
IL-13 22.1 (14.5) 16.2 (9.5) .098
RANTES 22.5 (17.0) 11.7 (9.8) .045
IP-10 2787.6 (1397.7) 2015.2 (499.6) .151
MCP-1 36.1 (23.5) 67.1 (69.0) .670
IL-4 13.9 (13.9) 4.5 (3.2) .002
MIP-1a 0.6 (0.7) 0.2 (0.1) .002
IL-6 5.3 (5.9) 2.1 (1.7) .003
IL-10 3.8 (2.1) 2.7 (1.2) .005
IL-17a 0.6 (0.6) 0.4 (0.3) .296
MMP-9 1425.2 (1587.2) 935.6 (693.6) .213
IL-8 101.0 (46.5) 39.8 (22.2) .151
* P value comparing patients with Schirmer I test score 8 mm versus >8 mm at baseline (Student’s t-test).
IL ¼ interleukin; IFN ¼ interferon; IP ¼ interferon-gammaeinduced protein; MCP ¼ monocyte chemotactic protein; MIP ¼ macrophage in-
ﬂammatory protein; MMP ¼ matrix metalloproteinase; RANTES ¼ regulated on activation, normal T-cell expressed and secreted; SD ¼ standard
deviation; TNF ¼ tumor necrosis factor.
DRY EYE SIGNS, SYMPTOMS, AND TEAR CYTOKINES AFTER PUNCTAL OCCLUSION / Tong, et allenticule extraction33 and corneal graft procedures.34 Punc-
tal occlusion, a common treatment option for patients with
dry eye, has been shown to improve clinical signs and symp-
toms.13-15 Changes in tear cytokine levels and associations
with signs and symptoms after insertion of punctal plugs
have not been fully elucidated.
After bilateral punctal plug insertion in our study,
patients with dry eye demonstrated improvements in irrita-
tive symptoms, as well as reductions in central, superior,
nasal, and temporal corneal staining. Increased tear reten-
tion following punctal occlusion may have improved wound
healing due to reduced frictional forces during blinking,
which could have contributed to the reduction in corneal
epithelial staining. However, there was no change in inferior
zone corneal staining. The inferior cornea where initial tear
breakup occurs is prone to tear ﬁlm instability due to
meniscus suction effects and as a result, may be more resis-
tant to improvements in corneal staining. Despite some of
these improvements in symptoms and signs, the overall
tear cytokine levels were not signiﬁcantly altered following
insertion of punctal plugs.
A low Schirmer I test score (8 mm) was found to be
the factor most consistently associated with higher cytokineTHE OCULAR SURFACE / APRIL 2016, VOLlevels at baseline. Cytokine levels elevated at baseline in pa-
tients with low Schirmer I test scores remained high after
punctal occlusion, including the T helper type 1 cytokines
TNF-a, IL-1b, and IFN-g. There was no association be-
tween baseline cytokine or MMP-9 levels and baseline global
irritation symptoms scores or TFBUT, and no consistent as-
sociations with baseline ﬂuorescein staining. Multivariate
analyses revealed some association between changes in
global irritative symptoms with changes in IP-10 and
MIP-1a cytokine levels after punctal occlusion. Adverse
events typically experienced with punctal plugs, such as epi-
phora, foreign body sensation, eye irritation, and sponta-
neous plug loss,35 were not reported during this 3-week
study.
Control cases with patients using eye drops only with no
punctal occlusion were not included, since our study was
not evaluating the therapeutic efﬁcacy of punctal plugs
compared to lubricating drops which has been addressed
in other studies.36-38 Limitations of this study include its
small sample size and short duration. Additional studies
enrolling a larger population conducted over a longer period
of time are needed to conﬁrm the effects of punctal occlu-
sion that were observed on tear protein levels and. 14 NO. 2 / www.theocularsurface.com 239
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Figure 4. Changes in interferon-gammaeinducible protein (IP)-10 and
macrophage inﬂammatory protein (MIP)-1a levels in dry eye symptom
responders and non-responders. IP-10 (top) and MIP-1a (bottom) levels
were generally higher at baseline, and at week 1 and week 3, among
patients who demonstrated improvements in global irritation symptoms
score (responders) compared with those without signiﬁcant improve-
ment in global irritation symptoms score (non-responders) after punctal
occlusion. Responders were patients with improvement in symptoms
after occlusion where global symptom scores at week 3 minus week
0 were <0. Data points represent mean  standard error.
DRY EYE SIGNS, SYMPTOMS, AND TEAR CYTOKINES AFTER PUNCTAL OCCLUSION / Tong, et alinﬂammation, and the association with other disease charac-
teristics. Studies evaluating concurrent treatment with punc-
tal plugs and anti-inﬂammatory eye drops are also
warranted. The use of Schirmer test strips to collect tear pro-
tein samples may also have inadvertently included proteins
from the conjunctival epithelium, which may have resulted
from injury during test strip-insertion. Tear meniscus height
and conjunctivochalasis, which were not measured in this
study, could be assessed in future studies evaluating effects
of punctal occlusion on tear inﬂammatory proteins.
Our ﬁndings indicate that ocular inﬂammation is not
relieved by insertion of punctal plugs. Blockage of tear
drainage using punctal plugs may have resulted in retention
of proinﬂammatory proteins, leading to pooling of cytokines
in the lower fornix and subsequent damage to the ocular
surface from ongoing inﬂammation. This mechanism may
be responsible for the persistent corneal staining in the infe-
rior zone seen in patients evaluated in our study. Similarly,
in a 17-day study of the effects of punctal occlusion,
decreased tear clearance was observed in the ﬁrst 3 days af-
ter insertion of punctal plugs.16 However, improvement in
tear clearance observed from day 3 to the study end suggests
that a reduction in tear clearance is unlikely to be the main240 THE OCULAR SURFACE / APRIL 2016, Vcause of the continued high levels of cytokines observed up
to 3 weeks after occlusion in our study. There is also a pos-
sibility that mechanically induced inﬂammation, due to con-
tact between the punctal occluder and the canalicular wall,
triggered production of cytokines and this may negate any
improvements in inﬂammation from the retention of tears.V. CONCLUSIONS
Punctal plugs do not directly address the underlying
ocular surface inﬂammation in dry eye disease. Novel treat-
ment strategies with cyclosporine, topical corticosteroids,
tacrolimus, tetracycline derivatives, and other anti-
inﬂammatories have been developed to target underlying in-
ﬂammatory pathways in dry eye.39-41 The lack of signiﬁcant
changes in cytokine levels and inferior corneal staining
following punctal occlusion observed in this study suggests
that patients with dry eye may beneﬁt from earlier treatment
or concurrent instillation of anti-inﬂammatory agents with
punctal plugs12 for management of their disease.
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